Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells

BACKGROUND: Gemcitabine is the standard first-line chemotherapy regimen for pancreatic cancer. However, its therapeutic value is substantially limited in pancreatic cancer patients due to occurrence of resistance towards gemcitabine. A strategy of combined chemo-regimens is widely employed in clinic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Biosci
Main Authors: Li, Hehe, Zhang, Zhengle, Gao, Chenggang, Wu, Shihong, Duan, Qingke, Wu, Heshui, Wang, Chunyou, Shen, Qiang, Yin, Tao
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6582499/
https://ncbi.nlm.nih.gov/pubmed/31244991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13578-019-0312-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados